While defective HRR is recognized to be an indicator for PARP inhibition therapy, it appears that oxidative stress and oxidative DNA damage in ovarian cancer cells may also be considered as potential markers for PARP inhibition-based therapy. Here, PARP1 is linked to ovarian carcinoma.